Search research articles
Contact Us
Filters
Showing results (51-60 of 77) with videos related to
Page
of 8
Sort By:
The Journal of Dermatological Treatment
|
May 21, 2026
Sustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitis
Emma Guttman-Yassky, Thomas Bieber, Kenji Kabashima, et al.
Acta Clinica Belgica
|
November 24, 2023
Belgian atopic dermatitis guidelines
Hilde Lapeere, Reinhart Speeckaert, Marie Baeck, et al.
The Journal of Dermatological Treatment
|
April 28, 2024
Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials
Jennifer Soung, Sonja Ständer, Jan Gutermuth, et al.
Allergy
|
August 9, 2023
Autoreactive IgE: Pathogenic role and therapeutic target in autoimmune diseases
Nicolas Charles, Inge Kortekaas-Krohn, Emek Kocaturk, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
May 6, 2022
A Novel Method for Total IgE Purification from Human Serum
Fariza Mishaal Saiema Badloe, Shauni De Vriese, Tina De Bruyn Carlier, et al.
The Journal of Investigative Dermatology
|
November 12, 2013
Reversal of CD8 T-cell-mediated mucocutaneous graft-versus-host-like disease by the JAK inhibitor tofacitinib
Naoko Okiyama, Yasuko Furumoto, Vadim A Villarroel, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
June 10, 2024
The doctor will see you now, in 4 months: A Belgian perspective on waiting times for dermatologic care
Jo Lambert, Julien Lambert, Koen Roegies, et al.
Clinical and Experimental Dermatology
|
December 16, 2024
Improved quality of life in patients treated with lebrikizumab monotherapy is mediated by improvements in itch and sleep: results from two phase III trials in patients with moderate-to-severe atopic dermatitis
Gil Yosipovitch, Marjolein de Bruin-Weller, Marni Wiseman, et al.
American Journal of Clinical Dermatology
|
July 20, 2022
Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis
Jonathan I Silverberg, David N Adam, Matthew Zirwas, et al.
Dermatology and Therapy
|
June 26, 2024
Lebrikizumab Improves Quality of Life and Patient-Reported Symptoms of Anxiety and Depression in Patients with Moderate-to-Severe Atopic Dermatitis
Peter A Lio, April Armstrong, Jan Gutermuth, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 77) with videos related to
Sort By:
Page
of 8
The Journal of Dermatological Treatment
|
May 21, 2026
Sustained on/off-treatment disease control with abrocitinib for moderate-to-severe atopic dermatitis
Emma Guttman-Yassky, Thomas Bieber, Kenji Kabashima, et al.
Acta Clinica Belgica
|
November 24, 2023
Belgian atopic dermatitis guidelines
Hilde Lapeere, Reinhart Speeckaert, Marie Baeck, et al.
The Journal of Dermatological Treatment
|
April 28, 2024
Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials
Jennifer Soung, Sonja Ständer, Jan Gutermuth, et al.
Allergy
|
August 9, 2023
Autoreactive IgE: Pathogenic role and therapeutic target in autoimmune diseases
Nicolas Charles, Inge Kortekaas-Krohn, Emek Kocaturk, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
May 6, 2022
A Novel Method for Total IgE Purification from Human Serum
Fariza Mishaal Saiema Badloe, Shauni De Vriese, Tina De Bruyn Carlier, et al.
The Journal of Investigative Dermatology
|
November 12, 2013
Reversal of CD8 T-cell-mediated mucocutaneous graft-versus-host-like disease by the JAK inhibitor tofacitinib
Naoko Okiyama, Yasuko Furumoto, Vadim A Villarroel, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
June 10, 2024
The doctor will see you now, in 4 months: A Belgian perspective on waiting times for dermatologic care
Jo Lambert, Julien Lambert, Koen Roegies, et al.
Clinical and Experimental Dermatology
|
December 16, 2024
Improved quality of life in patients treated with lebrikizumab monotherapy is mediated by improvements in itch and sleep: results from two phase III trials in patients with moderate-to-severe atopic dermatitis
Gil Yosipovitch, Marjolein de Bruin-Weller, Marni Wiseman, et al.
American Journal of Clinical Dermatology
|
July 20, 2022
Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis
Jonathan I Silverberg, David N Adam, Matthew Zirwas, et al.
Dermatology and Therapy
|
June 26, 2024
Lebrikizumab Improves Quality of Life and Patient-Reported Symptoms of Anxiety and Depression in Patients with Moderate-to-Severe Atopic Dermatitis
Peter A Lio, April Armstrong, Jan Gutermuth, et al.
Page
of 8